1AD Stock Overview
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia.
AdAlta Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.056|
|52 Week High||AU$0.092|
|52 Week Low||AU$0.042|
|1 Month Change||19.15%|
|3 Month Change||19.15%|
|1 Year Change||-30.86%|
|3 Year Change||-46.67%|
|5 Year Change||-74.54%|
|Change since IPO||-80.00%|
Recent News & Updates
Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For NowNov 16
Is AdAlta (ASX:1AD) Using Debt Sensibly?Sep 02
|1AD||AU Biotechs||AU Market|
Return vs Industry: 1AD underperformed the Australian Biotechs industry which returned -5.4% over the past year.
Return vs Market: 1AD underperformed the Australian Market which returned -5.2% over the past year.
|1AD Average Weekly Movement||9.5%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||8.9%|
|10% most volatile stocks in AU Market||15.8%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: 1AD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 1AD's weekly volatility (10%) has been stable over the past year.
About the Company
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company’s lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd.
AdAlta Limited Fundamentals Summary
|1AD fundamental statistics|
Is 1AD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1AD income statement (TTM)|
|Cost of Revenue||AU$260.61k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.019|
|Net Profit Margin||-220.11%|
How did 1AD perform over the long term?See historical performance and comparison